论文部分内容阅读
目的 :探讨不同尿激酶剂量对无框架立体定向机器人治疗高血压脑出血的临床疗效。方法:将2010年6月致2016年6月在新疆生产建设兵团医院神经外科符合纳入排除标准的120例高血压脑出血患者随机分为三组,1万单位组、3万单位组、5万单位组,每组各40例,每天两次注入尿激酶,每次夹管2小时。结果:3万单位组、5万单位组血肿清除率高于1万单位组,差异有统计学意义(p<0.05),而置管天数、尿激酶注入次数均少于1万单位组,差异有统计学意义(p<0.05)。5万单位组再出血率较1万3万单位组的高,差异有统计学意义,(p<0.05)。感染率3组间差异无统计学意义,(p>0.05)。结论:血肿腔每日两次注射尿激酶3万单位时,高血压脑出血患者治疗效果最佳,并发症最少。
Objective: To investigate the clinical effect of different urokinase doses on hypertensive intracerebral hemorrhage in frameless stereotactic robots. Methods: One hundred and twenty cases of hypertensive intracerebral hemorrhage who met the criteria of neurosurgery in Xinjiang Production and Construction Corps Hospital in June, 2016 were randomly divided into three groups: 10,000 units, 30,000 units and 50,000 Unit group, 40 cases in each group, urokinase twice a day, each pinch 2 hours. Results: The hematoma clearance rate of 30000 unit group and 50000 unit group was higher than 10000 unit group, the difference was statistically significant (p <0.05), while the number of days of catheterization and urokinase injection were less than 10000 unit group, the difference There was statistical significance (p <0.05). The rebleeding rate of 50,000 units was higher than that of 130,000 units (p <0.05). There was no significant difference in infection rate among the three groups (p> 0.05). Conclusions: Hypertensive intracerebral hemorrhage has the best treatment and minimal complication when hematoma cavity is injected with 30,000 units of urokinase twice daily.